Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriComB trial of trifluridine/tipiracil + capecitabine + bevacizumab in metastatic colorectal cancer
2024-513271-41-00Phase 2Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil, capecitabine and bevacizumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Objective Response Rate. Planned start Sep 2024; status: authorised.
02
Drugs
trifluridine + tipiracilcapecitabinebevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-513271-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513271-41-00.